{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:59:13Z","timestamp":1790650753729,"version":"4.1.0"},"reference-count":49,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"unspecified","delay-in-days":145,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"C.R.E.B.S \/ Centre de Recherche d\u2019Etudes Biologiques et Sociales et Scientifiques","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2026,4,25]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>\n                      Device-aided therapies (DAT) have significantly improved the management of Parkinson\u2019s disease (PD). They now include deep brain stimulation (DBS), levodopa\u2013carbidopa intestinal gel (LCIG) infusion, continuous subcutaneous apomorphine infusion (CSAI), subcutaneous foslevodopa\/foscarbidopa and levodopa\u2013entacapone\u2013carbidopa intestinal gel (LECIG) infusions. Despite established clinical benefits, disparities in DAT access and use have been reported across Europe and the USA. The PARKinson's Device-Aided-Therapies (PARK-DAT) study aimed to evaluate access to and use of DAT (DBS, LCIG and CSAI) for PD in France between 2015 and 2021 using data from the French national administrative healthcare database (\n                      <jats:italic>Syst\u00e8me National des Donn\u00e9es de Sant\u00e9<\/jats:italic>\n                      , SNDS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PARK-DAT is a nationwide, retrospective observational study. Patients with PD who initiated any DAT for the first time between 2015 and 2021 were identified using an established algorithm and codes within the SNDS. Standardised incidences of DAT initiation were calculated by study period and geographical region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between 2015 and 2021 8829 patients with PD (mean age 68.7\u00b110.3 years; 43.4%\u2009women) initiated DAT representing a 41.8% overall increase between 2015 and 2021. CSAI was the most frequently initiated therapy (6873 patients; +58.9%), followed by DBS (1592 patients; \u221220.7%) and LCIG (364 patients; +152.9%). Most DAT prescriptions originated from hospital centres (74.6%). Few therapy switches or combinations were observed, mainly involving CSAI. Regional analyses suggest incidence disparities in DAT access.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Unlike patterns observed in other countries, CSAI was the predominant DAT in France, while DBS use declined. Features of the French healthcare system, including favourable reimbursement and broad access to home nursing services, may account for this distinctive distribution.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjno-2026-001577","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:23:35Z","timestamp":1779805415000},"page":"e001577","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Nationwide analysis of real-world access to and use of device-aided therapies in Parkinson\u2019s disease: insights from the French National Healthcare Data System (2015\u20132021)"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7003-4084","authenticated-orcid":false,"given":"Manon","family":"Auffret","sequence":"first","affiliation":[{"name":"CIC 1414, CHU de Rennes \u2013 Universit\u00e9 de Rennes, Rennes, France"},{"name":"France D\u00e9veloppement Electronique (FDE), Monswiller, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Nowak","sequence":"additional","affiliation":[{"name":"DAMAD, Plouzan\u00e9, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"V\u00e9rin","sequence":"additional","affiliation":[{"name":"Neurology, CHU d\u2019Orl\u00e9ans, Orl\u00e9ans, Centre-Val de Loire, France"},{"name":"Brain-Clinicial and Experimental Neuroplasticity (B-CLINE), Laboratoire Interdisciplinaire pour l\u2019Innovation et la Recherche en Sant\u00e9 d\u2019Orl\u00e9ans (LI2RSO), Universit\u00e9 d\u2019Orl\u00e9ans, Orl\u00e9ans, Centre-Val de Loire, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Kerbrat","sequence":"additional","affiliation":[{"name":"DAMAD, Plouzan\u00e9, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"2026052607101046000_8.1.e001577.1","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00702-023-02668-9","article-title":"Access to device-aided therapies in advanced Parkinson\u2019s disease: navigating clinician biases, patient preference, and prognostic uncertainty","volume":"130","author":"Auffret","year":"2023","journal-title":"J Neural Transm (Vienna)"},{"key":"2026052607101046000_8.1.e001577.2","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-023-00525-w","article-title":"A single centre prospective study of three device-assisted therapies for Parkinson\u2019s disease","volume":"9","author":"Morales-Brice\u00f1o","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"key":"2026052607101046000_8.1.e001577.3","doi-asserted-by":"crossref","first-page":"107872","DOI":"10.1016\/j.parkreldis.2025.107872","article-title":"Apomorphine: past, present and future in Parkinson\u2019s disease and beyond","volume":"139","author":"Auffret","year":"2025","journal-title":"Parkinsonism Relat Disord"},{"key":"2026052607101046000_8.1.e001577.4","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1007\/s10072-021-05106-4","article-title":"Device-aided therapies for advanced Parkinson disease: insights from an international survey","volume":"42","author":"Marsili","year":"2021","journal-title":"Neurol Sci"},{"key":"2026052607101046000_8.1.e001577.5","doi-asserted-by":"crossref","first-page":"100599","DOI":"10.1016\/j.lana.2023.100599","article-title":"Trends and disparities in deep brain stimulation utilization in the United States: a Nationwide Inpatient Sample analysis from 1993 to 2017","volume":"26","author":"Sarica","year":"2023","journal-title":"The Lancet Regional Health - Americas"},{"key":"2026052607101046000_8.1.e001577.6","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/mdc3.12988","article-title":"Access and Use of Device-Aided Therapies for Parkinson\u2019s Disease in Denmark","volume":"7","author":"Henriksen","year":"2020","journal-title":"Mov Disord Clin Pract"},{"key":"2026052607101046000_8.1.e001577.7","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13050736","article-title":"Device-Aided Therapies in Parkinson\u2019s Disease-Results from the German Care4PD Study","volume":"13","author":"Fr\u00fcndt","year":"2023","journal-title":"Brain Sci"},{"key":"2026052607101046000_8.1.e001577.8","first-page":"e2078","article-title":"Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease","volume":"101","author":"P\u00fcrner","year":"2023","journal-title":"Neurology (ECronicon)"},{"key":"2026052607101046000_8.1.e001577.9","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40120-025-00730-0","article-title":"Therapies for Advanced Parkinson\u2019s Disease in Sweden: A Cost-Effectiveness Analysis Using Real-World Data","volume":"14","author":"Nyholm","year":"2025","journal-title":"Neurol Ther"},{"key":"2026052607101046000_8.1.e001577.10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.14802\/jmd.23172","article-title":"Accessibility of Device-Aided Therapies for Persons With Parkinson\u2019s Disease in Poland","volume":"17","author":"Smilowska","year":"2024","journal-title":"JMD"},{"key":"2026052607101046000_8.1.e001577.11","doi-asserted-by":"crossref","first-page":"107322","DOI":"10.1016\/j.parkreldis.2025.107322","article-title":"Association of patient characteristics, social drivers of health, and geographic location on access to device-aided therapies among medicare beneficiaries with advanced Parkinson\u2019s disease","volume":"133","author":"Jimenez-Shahed","year":"2025","journal-title":"Parkinsonism Relat Disord"},{"key":"2026052607101046000_8.1.e001577.12","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70024","article-title":"How well is the female population represented in clinical trials with infusion therapies for Parkinson\u2019s disease? A systematic review and metanalysis","volume":"32","author":"Smilowska","year":"2025","journal-title":"Eur J Neurol"},{"key":"2026052607101046000_8.1.e001577.13","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1498756","article-title":"Global, regional, national epidemiology and trends of Parkinson\u2019s disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021","volume":"16","author":"Luo","year":"2024","journal-title":"Front Aging Neurosci"},{"key":"2026052607101046000_8.1.e001577.14","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-019-1276-8","article-title":"Characterizing advanced Parkinson\u2019s disease: OBSERVE-PD observational study results of 2615 patients","volume":"19","author":"Fasano","year":"2019","journal-title":"BMC Neurol"},{"key":"2026052607101046000_8.1.e001577.15","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00702-023-02609-6","article-title":"Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson\u2019s disease: the APOKADO study","volume":"130","author":"Zagnoli","year":"2023","journal-title":"J Neural Transm (Vienna)"},{"key":"2026052607101046000_8.1.e001577.16","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s12325-019-01014-4","article-title":"Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson\u2019s Disease in the United States","volume":"36","author":"Amjad","year":"2019","journal-title":"Adv Ther"},{"key":"2026052607101046000_8.1.e001577.17","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-024-00667-5","article-title":"Disease progression strikingly differs in research and real-world Parkinson\u2019s populations","volume":"10","author":"Beaulieu-Jones","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"key":"2026052607101046000_8.1.e001577.18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.parkreldis.2021.03.006","article-title":"Analysis of nationwide multimodal complex treatment and drug pump therapy in Parkinson\u2019s disease in times of COVID-19 pandemic in Germany","volume":"85","author":"Richter","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"key":"2026052607101046000_8.1.e001577.19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.parkreldis.2021.10.011","article-title":"North American survey on impact of the COVID-19 pandemic shutdown on DBS care","volume":"92","author":"Siddiqui","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"key":"2026052607101046000_8.1.e001577.20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.therap.2018.09.072","article-title":"French administrative health care database (SNDS): The value of its enrichment","volume":"74","author":"Scailteux","year":"2019","journal-title":"Therapie"},{"key":"2026052607101046000_8.1.e001577.21","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.therap.2024.05.003","article-title":"Use of the French National Health Data System (SNDS) in pharmacoepidemiology: A systematic review in its maturation phase","volume":"79","author":"Maillard","year":"2024","journal-title":"Therapies"},{"key":"2026052607101046000_8.1.e001577.22","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4233"},{"key":"2026052607101046000_8.1.e001577.23","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: From the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France","volume":"65 Suppl 4","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"key":"2026052607101046000_8.1.e001577.24","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000001745"},{"key":"2026052607101046000_8.1.e001577.25","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.therap.2024.05.001","article-title":"What is the best source for searching drug with CIP codes in the French health reimbursement data system (SNDS) database?","volume":"79","author":"Couderc","year":"2024","journal-title":"Therapie"},{"key":"2026052607101046000_8.1.e001577.26","doi-asserted-by":"publisher","DOI":"10.1159\/000521288"},{"key":"2026052607101046000_8.1.e001577.27","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000471"},{"key":"2026052607101046000_8.1.e001577.28","doi-asserted-by":"crossref","first-page":"105859","DOI":"10.1016\/j.parkreldis.2023.105859","article-title":"Discontinuation rate and long-term adverse events path of apomorphine infusion in advanced Parkinson\u2019s disease patients","volume":"116","author":"Camgrand","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"key":"2026052607101046000_8.1.e001577.29","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1177\/1877718X251344896","article-title":"Twenty-five-year experience with apomorphine pump in Parkinson\u2019s disease: A real-life long-term retrospective tolerance study","volume":"15","author":"Potel","year":"2025","journal-title":"J Parkinsons Dis"},{"key":"2026052607101046000_8.1.e001577.30","doi-asserted-by":"crossref","first-page":"108214","DOI":"10.1016\/j.parkreldis.2026.108214","article-title":"Continuous subcutaneous apomorphine infusion to improve comfort in advanced degenerative Parkinsonian syndrome patients: a retrospective descriptive study in a home-based setting","volume":"144","author":"Singovski","year":"2026","journal-title":"Parkinsonism Relat Disord"},{"key":"2026052607101046000_8.1.e001577.31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/mdc3.70239","article-title":"Profile of People With Parkinson\u2019s Disease Treated With a Device-Aided Therapy in Spain. A Comparative Multicenter Observational Study","volume":"13","author":"Santos-Garc\u00eda","year":"2026","journal-title":"Mov Disord Clin Pract"},{"key":"2026052607101046000_8.1.e001577.32","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/mdc3.70074","article-title":"Use of and Barriers to Subcutaneous Apomorphine Pen Injections in Parkinson\u2019s Disease: A Survey by the French NS-PARK Network","volume":"12","author":"Aubignat","year":"2025","journal-title":"Mov Disord Clin Pract"},{"key":"2026052607101046000_8.1.e001577.33","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/mdc3.13582","article-title":"Clozapine Is Severely Underused in Parkinson\u2019s Disease Patients","volume":"9","author":"Friedman","year":"2022","journal-title":"Mov Disord Clin Pract"},{"key":"2026052607101046000_8.1.e001577.34","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2025.101569","article-title":"Management of Parkinson\u2019s disease psychosis-a European perspective","volume":"62","author":"Pirker","year":"2026","journal-title":"Lancet Reg Health Eur"},{"key":"2026052607101046000_8.1.e001577.35","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s00702-023-02686-7","article-title":"Practical use of apomorphine infusion in Parkinson\u2019s disease: lessons from the TOLEDO study and clinical experience","volume":"130","author":"Henriksen","year":"2023","journal-title":"J Neural Transm (Vienna)"},{"key":"2026052607101046000_8.1.e001577.36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.parkreldis.2022.05.018","article-title":"Use of levodopa-carbidopa intestinal gel to treat patients with multiple system atrophy","volume":"100","author":"Blaise","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"key":"2026052607101046000_8.1.e001577.37","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.parkreldis.2021.11.026","article-title":"Subcutaneous apomorphine in the treatment of progressive supranuclear palsy and corticobasal syndrome: A preliminary study of 7 cases","volume":"95","author":"Hubsch","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"key":"2026052607101046000_8.1.e001577.38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/mds.30105","article-title":"To Trust or Not to Trust? ICD-Coded Diagnosis of Parkinson\u2019s Disease","volume":"40","author":"Lo","year":"2025","journal-title":"Mov Disord"},{"key":"2026052607101046000_8.1.e001577.39","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1449973","article-title":"Ameliorating motor performance and quality of life in Parkinson\u2019s disease: a comparison of deep brain stimulation and focused ultrasound surgery","volume":"16","author":"Liang","year":"2025","journal-title":"Front Neurol"},{"key":"2026052607101046000_8.1.e001577.40","unstructured":"Ginneken E , Reed S , Siciliani L , et al . Addressing Backlogs and Managing Waiting Lists during and beyond the COVID-19 Pandemic. Copenhagen (Denmark): European Observatory on Health Systems and Policies, 2022. Available: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK589255\/ [accessed 13 Aug 2025]."},{"key":"2026052607101046000_8.1.e001577.41","doi-asserted-by":"crossref","unstructured":"Aslam S , Sharrief AZ , Holden SK , et al . The future of Parkinson\u2019s care: a need to expand access. Front Neurol 2025;16. doi:10.3389\/fneur.2025.1622283","DOI":"10.3389\/fneur.2025.1622283"},{"key":"2026052607101046000_8.1.e001577.42","doi-asserted-by":"crossref","first-page":"107889","DOI":"10.1016\/j.parkreldis.2025.107889","article-title":"No one size fits all approach with apomorphine initiation","volume":"139 Suppl 1","author":"Kobylecki","year":"2025","journal-title":"Parkinsonism Relat Disord"},{"key":"2026052607101046000_8.1.e001577.43","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.3233\/JPD-230224","article-title":"Parkinson\u2019s Nurses Are Crucial for the Management of Parkinson\u2019s Disease: 2007-2024","volume":"14","author":"Thomas","year":"2024","journal-title":"J Parkinsons Dis"},{"key":"2026052607101046000_8.1.e001577.44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5603\/pjnns.102858","article-title":"Long-term effect and reasons for switching and combining device-aided therapies in Parkinson\u2019s Disease","volume":"59","author":"Georgiev","year":"2025","journal-title":"Neurol Neurochir Pol"},{"key":"2026052607101046000_8.1.e001577.45","first-page":"1","article-title":"France: Health System Review","volume":"17","author":"Chevreul","year":"2015","journal-title":"Health Syst Transit"},{"key":"2026052607101046000_8.1.e001577.46","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.r997","article-title":"Discrimination is widespread in French healthcare, report alleges","volume":"389","author":"Casassus","year":"2025","journal-title":"BMJ"},{"key":"2026052607101046000_8.1.e001577.47","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1111\/ene.15391","article-title":"The European Academy of Neurology Brain Health Strategy: One brain, one life, one approach","volume":"29","author":"Bassetti","year":"2022","journal-title":"Euro J of Neurology"},{"key":"2026052607101046000_8.1.e001577.48","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.neurol.2025.07.014","article-title":"Training in movement disorders during neurology residency in France: A national survey on educational gaps and future perspectives","volume":"181","author":"Aubignat","year":"2025","journal-title":"Rev Neurol (Paris)"},{"key":"2026052607101046000_8.1.e001577.49","unstructured":"Dahodwala N , Kapogiannis T , Cruz A , et al . Longitudinal study of treatment variability for parkinson\u2019s disease across specialized centers. movement disorders clinical practice. Available: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/mdc3.70232 [Accessed 23 Oct 2025]."}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2026-001577","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:23:48Z","timestamp":1779805428000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2026-001577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,5,26]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjno-2026-001577"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2026-001577","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}